Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | RB1 del |
| Gene Variant Detail | |
| Relevant Treatment Approaches | HDAC Inhibitor |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06126276 | Phase II | Neratinib Neratinib + Palbociclib | Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial) | Recruiting | USA | 0 |
| NCT04926181 | Phase II | Apalutamide + Cetrelimab | Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer | Terminated | USA | 0 |
| NCT04471974 | Phase II | Enzalutamide + Pembrolizumab + ZEN-3694 | ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer | Active, not recruiting | USA | 0 |
| NCT05696626 | Phase III | Abemaciclib + Fulvestrant Abemaciclib + Lasofoxifene | Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation (ELAINEIII) | Recruiting | USA | TUR | ROU | POL | ITA | ISR | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 4 |
| NCT05867251 | Phase Ib/II | ARTS-021 + Fulvestrant + Ribociclib ARTS-021 + Letrozole + Ribociclib ARTS-021 + Fulvestrant + Palbociclib ARTS-021 + Letrozole + Palbociclib ARTS-021 + Carboplatin Abemaciclib + ARTS-021 + Fulvestrant Abemaciclib + ARTS-021 + Letrozole ARTS-021 + Fulvestrant ARTS-021 | Study of AVZO-021 in Patients With Advanced Solid Tumors | Recruiting | USA | AUS | 0 |
| NCT02546661 | Phase I | Danvatirsen + Durvalumab Durvalumab + Selumetinib Fexagratinib Durvalumab + Olaparib Durvalumab Durvalumab + Fexagratinib Durvalumab + Vistusertib Adavosertib + Durvalumab | Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer (BISCAY) | Active, not recruiting | USA | GBR | FRA | ESP | CAN | 0 |
| NCT04432454 | Phase II | Abemaciclib + Lasofoxifene | Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation (ELAINEII) | Completed | USA | 0 |
| NCT05843253 | Phase II | Ribociclib + Temozolomide Everolimus + Ribociclib | Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant | Recruiting | USA | NLD | GBR | DEU | CAN | AUS | 0 |